1. Quinn T Ostrom, Mackenzie Price, Corey Neff, Gino Cioffi, Kristin A Waite, Carol Kruchko, Jill S Barnholtz-Sloan, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016—2020, Neuro-Oncology, Volume 25, Issue Supplement_4, October 2023, Pages iv1–iv99, https://doi.org/10.1093/neuonc/noad149
2. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России. 2021.
3. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. World Health Organization Histological Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, France, 2016
4. Гусев Е.И. Коновалов А.Н., Скворцова В.И., Гехт А.Б., ред. Неврология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009.
5. Чиссов В.И., Давыдов М.И., ред. Онкология: национальное руководство. М.: ГЭОТАР-Медиа, 2008.
6. Корниенко В.Н., Пронин И.Н. Диагностическая нейрорадиология. В 4-х тт. М.: 2008–2012.
7. Приказ Министерства здравоохранения Российской Федерации от 19.02.2021 г. N 116н «Об утверждении Порядка оказания медицинской помощи взрослому населению при онкологических заболеваниях» (зарегистрирован 01.04.2021 г. № 62964).
8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Central Nervous System Cancers. 2021.
9. Kortmann R.D. Current concepts and future strategies in the management of intracranial germinoma. Expert Rev Anticancer Ther 2014;14:105–19.
10. HIT-MED Therapy Guidance Version 4.0–0.2, May 2017.
11. Лошаков В.А., Жуков В.Ю., Пронин И.Н., и др. Планирование хирургического доступа при удалении внутримозговых опухолей больших полушарий с использованием фМРТ, навигационных систем и электрофизиологического мониторинга. Вопр. нейрохирургии им. Н.Н. Бурденко 2010;(2):9–13.
12. Меликян А.Г. Стереотаксические методы в диагностике и лечении опухолей головного мозга. Дис. … д-ра мед. наук. М.: 1997.
13. Практические рекомендации по лечению злокачественных опухолей Российского общества клинической онкологии (RUSSCO). М.: 2017.
14. De Witt Hamer P.C., Robles S.G., Zwinderman A.H., et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559–65. DOI: 10.1200/JCO.2011.38.4818
15. Stummer W., Pichlmeier U., Meinel T., et al. ALA-Glioma Study Group. Fluorescence- guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392–401.
16. Горяйнов С.А., Потапов А.А., Пицхелаури Д.И., и др. Интраоперационная флуоресцентная диагностика и лазерная спектроскопия при повторных операциях по поводу глиом головного мозга. Вопр. нейрохирургии им. Н.Н. Бурденко 2014;2:18–25.
17. Кобяков Г.Л. Химиотерапия в комплексном лечении больных с первичными злокачественными опухолями головного мозга. Дис. … д-ра мед. наук. М.: 2012.
18. Osorio D.S., Allen J.C. Management of CNS germinoma. CNS Oncol. 2015;4(4):273–9.
19. Кобяков Г.Л., Абсалямова О.В., Аникеева О.Ю., Бекяшев А.Х., Голанов А.В., Коновалов А.Н., и др. Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной системы. Злокачественные опухоли 2015;4(Спецвыпуск)55–79.
20. Gupta N, Pediatric CNS Tumors. Pediatric Oncology, Springer 3rd ed., 2017.
21. Carachi R. The Surgery of Childhood Tumors. Springer, 3rd ed., 2008.
22. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Lancet Oncol 2009;10(5):459–66.
23. Stupp R., Brada M., van den Bent MJ. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii93–101.
24. Birk H., Han S., Butowski N. Treatment options for recurrent high-grade glioma. CNS Oncol. 2017;6(1):61–70.
25. Taal W., Oosterkamp H.M., Walenkamp A.M., et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014;15(9):943–53. DOI: 10.1016/S1470-2045(14)70314-6
26. Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253–9.
27. Nonoguchi N., Ohta T., Oh J.E., Kim Y.H., Kleihues P., Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013;126:931–7. DOI: 10.1007/s00401-013-1163-0
28. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733–40.
29. Angelov L., Doolittle N., Kraemer D., et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi- institutional experience. JCO 2009:3503–9.
30. DeAngelis L.M., Seiferheld W., Schold S.C., et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 2002;20:4643–8.
31. Winn H.R., ed. Kunshner L.J., Lang F.F. Medulloblastoma. Youmans Neurological Surgery. 5th ed. Philadelphia, PA: Saunders, 2004;1:1031–42.
32. Wirsching H.G., Galanis E., Weller M. Glioblastoma. Handb Clin Neurol 2016;134:381–97. DOI: 10.1016/B978-0-12-802997-8.00023-2
33. Niyazi M., Brada M., et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol 2016;118:35-42.
34. Трофимова Т.Н. Нейрорадиология: Оценка эффективности хирургии и комбинированной терапии глиом. Практическая онкология 2016;17(1):32–40.
35. Lee N.Y., Lu J.J., eds. Target volume delineation and field setup: a practical guide for conformal and intensity-modulated radiation therapy. Springer-Verlag; 2013. DOI: 10.1007/174_2014_1005
36. Goldbrunner R., Minniti G., Preusser M. EANO guidelines for diagnosis and treatment of meningiomas. Lancet Oncol 2016;17(9):e383–91.
37. Галкин М.В. Стереотаксическая лучевая терапия в лечении менингиом медиальных отделов средней черепной ямки. Дис. … канд. мед. наук. М.: 2011.
38. Когония Л.М., Волошин А.Г., Новиков Г.А., Сидоров А.В. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018;8:617–35.
39. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Adult Cancer Pain. Version 3, 2019.
40. Сомонова О.В., Антух Э.А., Елизарова А.Л., Матвеева И.И., Сельчук В.Ю., Черкасов В.А. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018;8:604–9.
41. NCCN Clinical Practice Guidelines in Oncology ((NCCN Guidelines®). Cancer Associated Venous Thromboembolic Disease. Version 3, 2019
42. Sourati A., Ameri A. Acute Side Effects of Radiation Therapy: A Guide To Management. Springer, 2017.
43. Vargo M. Brain Tumor Rehabilitation. Am J Phys Med Rehabil 2011;90(5 Suppl 1):S50–62.
44. Харченко В.П., Паньшин Г.А., Сотников В.М., Измайлов Т.Р. Новые режимы лучевой терапии злокачественных опухолей головного мозга. Разрешение ФС №2009/147 от 11.06.2009 г.
45. Wick W., et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707–15.
46. Malmström A. et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13(9):916–26.
47. Louis, D.N., et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231–51. DOI: 10.1093/neuonc/noab106
48. She L, Su L, Liu C. Bevacizumab combined with re-irradiation in recurrent glioblastoma. Front Oncol. 2022 Aug 4;12:961014. doi: 10.3389/fonc.2022.961014. PMID: 36046037; PMCID: PMC9423039.
49. Rutkowski, M.J., et al. Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series. World Neurosurg 2016;95 368–74. doi:10.1016/j.wneu.2016.07.068
50. Weller M., Pfister S.M., Wick W., Hegi M.E., Reifenberger G., Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013;14(9):e370–9. DOI: 10.1016/S1470-2045(13)70168-2
51. Dubbink H.J., Atmodimedjo P.N., Kros J.M., French P.J., Sanson M., Idbaih, A., et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Оncol 2016;18(3):388–400. DOI: 10.1093/neuonc/nov182
52. Hartmann C., Hentschel B., Wick W., Capper D., Felsberg J., Simon M., et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta neuropathol 2010;120(6):707–18. DOI: 10.1007/s00401-010-0781-z
53. Hartmann C., Meyer J., Balss J., Capper D., Mueller W., Christians A., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathol 2009;118(4):469–74. DOI: 10.1007/s00401-009-0561-9
54. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343(19):1350–4. DOI: 10.1056/NEJM200011093431901
55. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribole N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997–1003. DOI: 10.1056/NEJMoa043331
56. Sahm F., Reuss D., Koelsche C., Capper D., Schittenhelm J., Heim S., et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta neuropathol 2014;128(4):551–9. DOI: 10.1007/s00401-014-1326-7
57. van den Bent MJ., Brandes A.A., Taphoorn M.J.B., Kros J.M., Kouwenhoven M.C.M., Delattre J.-Y., et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31(3):344–50. DOI: 10.1200/JCO.2012.43.2229
58. Cairncross G., Wang M., Shaw E., Jenkins R., Brachman D., Buckner J., et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013;31(3):337–43. DOI: 10.1200/JCO.2012.43.2674
59. Reuss D.E., Sahm F., Schrimpf D., Wiestler B., Capper D., Koelsche C., et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta neuropathol 2015;129(1):133–46. DOI: 10.1007/s00401-014-1370-3
60. Nikiforova M.N., Wald A.I., Melan M.A., Roy S., Zhong S., Hamilton R.L., et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Оncol 2016;18(3):379–87. DOI: 10.1093/neuonc/nov289
61. Dougherty M.J., Santi M., Brose M.S., Ma C., Resnick A.C., Sievert A.J., et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Оncol 2010;12(7):621–30. DOI: 10.1093/neuonc/noq007
62. Schindler G., Capper D., Meyer J., Janzarik W., Omran H., Herold-Mende C., et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta neuropathol 2011;121(3):397–405. DOI: 10.1007/s00401-011-0802-6
63. Chi A.S., Batchelor T.T., Yang D., Dias-Santagata D., Borger D.R., Ellisen L.W., et al. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013;31(14):e233–6. DOI: 10.1200/JCO.2012.46.0220
64. Migliorini D., Aguiar D., Vargas M.-I., Lobrinus A., Dietrich P.-Y. BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma. Neurol 2017;88(13):1291–3. DOI: 10.1212/WNL.0000000000003767
65. Reni M., Brandes A.A., Vavassori V., Cavallo G., Casagrande F., et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors. Cancer 2004;100(6):1221–9. DOI: 10.1002/cncr.20074
66. Quant, E.C., Wen, P.Y. Response Assessment in Neuro-Oncology. Curr Oncol Rep 2010;13(1):50–6.
67. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649−55.
68. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C. (ed.). Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949:191–205.
69. Hawker G.A., Mian S., Kendzerska T., French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S240–52.
70. Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn , Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven, Pim French , Monika E Hegi, Asgeir S Jakola, Michael Platten, Patrick Roth, Roberta Rudà, Susan Short, Marion Smits, Martin J B Taphoorn, Andreas von Deimling, Manfred Westphal, Riccardo Soffietti, Guido Reifenberger, Wolfgang Wick. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Rev Clin Oncol. 2021 Mar;18(3):170-186. doi: 10.1038/s41571-020-00447-z. Epub 2020 Dec 8.
71. RUSSCO, Рекомендации по поддерживающей и сопроводительной терапии. ‒ 2024. – URL: https://rosoncoweb.ru/standarts/RUSSCO/2024/2024-1_1-10.pdf
72. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Central Nervous System Cancers. ‒ 2024. – URL: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.https://www.nccn.org/patients/guidelines/content/PDF/brain-gliomas-patient.pdf
73. Онкопсихология для врачей-онкологов и медицинских психологов. / А.М.Беляев, В.А.Чулкова, Т.Ю.Семиглазова, М.В.Рогачев. – Санкт Питербург: Ассоциация онкологов Северо-Западного федерального округа, 2017. – 352 c.
74. Fors MM, Viada CE, Gonzalez P. Use of Recursive Partitioning Analysis in Clinical Trials and Meta-Analysis of Randomized Clinical Trials, 1990-2016. Rev Recent Clin Trials. 2017;12(1):3-7. doi: 10.2174/1574887111666160916144658. PMID: 27633964.
75. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S, Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9. doi: 10.1200/JCO.2005.04.5963. PMID: 16735709.
76. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007 Aug 1;25(22):3357-61. doi: 10.1200/JCO.2007.10.7722. PMID: 17664483.
77. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589–601.
78. Manuel Diezi, Barry Pizer, Matthew J. Murray, Overview of current European practice for the management of patients with intracranial germ cell tumours, EJC Paediatric Oncology, Volume 3, 2024, 100146, ISSN 2772-610X, https://doi.org/10.1016/j.ejcped.2024
79. Нейрохирургия. Национальное руководство. Том IV. Нейроонкология/ Под ред. А.Н.Коновалова, Д.Ю.Усачева, Д.И.Пицхелаури, В.Н.Шимансковго, В.А.Черекаева, П.Л.Калинина, А.В.Голанова. - ФГАУ "Национальный миедицинский исследовательский центр нейрохирургии имени академика Н.Н.Бурденко" Министерства здравоохранения РФ, 2025 - стр. 432: ил.
80. Zoto Mustafayev T, Turna M, Bolukbasi Y, Tezcanli E, Guney Y, Dincbas FO, Atasoy BM, Ugurluer G, Caglar HB, Atalar B, Ozyar E. Clinical and radiological effects of Bevacizumab for the treatment of radionecrosis after stereotactic brain radiotherapy. BMC Cancer. 2024 Jul 30;24(1):918. doi: 10.1186/s12885-024-12643-6
81. Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K, Mittelbronn M. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320
82.Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023 Feb 20;41(6):1285-1295. doi: 10.1200/JCO.22.00164
83. Takei J, Fukasawa N, Tanaka T, Yamamoto Y, Tamura R, Sasaki H, Akasaki Y, Kamata Y, Murahashi M, Shimoda M, Murayama Y. Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas. Front Oncol. 2022 Jun 17;12:898614.
84. Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. PMID: 26847813.
85. Wick W, Platten M, Weller M. New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. PMID: 18772354; PMCID: PMC2718961.
86. Mrugala MM, Crew LK, Fink JR, Spence AM. Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett. 2012 Nov;4(5):1082-1086. doi: 10.3892/ol.2012.839. Epub 2012 Aug 1. PMID: 23162656; PMCID: PMC3499591
87. van der Meulen M, Chahal M, Mason WP. The Value of Etoposide for Recurrent Glioma. Can J Neurol Sci. 2024 Jul;51(4):509-512. doi: 10.1017/cjn.2023.276
88. Leonardo Rojas et al. Profiling response to carmustine/bevacizumab in recurrent glioblastoma. JCO 34, 2059-2059(2016). DOI:10.1200/JCO.2016.34.15_suppl.2059
89. Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, Ramón JF, Useche N, Bermúdez S, Pineda D, Cifuentes H, Rojas L, Ricaurte L, Pino LE, Balaña C, Arrieta O. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. PLoS One. 2019 Jun 20;14(6):e0217340. doi: 10.1371/journal.pone.0217340
90. Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010 May;97(3):389-92. doi: 10.1007/s11060-009-0032-0. Epub 2009 Oct 20. PMID: 19841864.
91. Li, Q., Wu, G., Sun, Z. et al. Temozolomide plus rituximab for elderly with relapsed primary central nervous system lymphoma. Chin. -Ger. J. Clin. Oncol. 10, 415–417 (2011). https://doi.org/10.1007/s10330-011-0803-x